{"analyses":[{"ciLowerLimit":"0.591","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.947","estimateComment":"Based on stratified Cox Regression model","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0077","paramType":"Hazard Ratio (HR)","paramValue":"0.748","statisticalMethod":"1-sided stratified log-rank test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"29.5","upperLimit":"39.8","value":"34.1"},{"groupId":"OG001","lowerLimit":"24.4","upperLimit":"31.6","value":"27.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"227"},{"groupId":"OG001","value":"225"}],"units":"Participants"}],"description":"OS was defined as the time from randomization to the date of death for any cause. In the absence of confirmation of death, survival time was censored at the last date the participant was known to be alive. OS (month)=\\[death date or last known alive date - randomization date + 1\\]/30.4375.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 45 mg of dacomitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first.","id":"OG000","title":"Dacomitinib"},{"description":"Participants received 250 mg of gefitinib tablets orally once daily in each treatment cycle of 28 days, for maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first.","id":"OG001","title":"Gefitinib"}],"paramType":"MEDIAN","populationDescription":"ITT Population included all randomized participants, with study treatment assignment designated according to initial randomization, regardless of whether participants received study treatment or a different treatment from that to which they were randomized.","reportingStatus":"POSTED","timeFrame":"From randomization until death or last date known as alive, up to 45 months","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}